VF
KPTI icon

Virtu Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Virtu Financial’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-667
Closed -$9K – 1755
2023
Q4 		$9K Buy
+667
New +$8.99K ﹤0.01% 1418
2022
Q3 		– Sell
-876
Closed -$59K – 1980
2022
Q2 		$59K Buy
+876
New +$80.3K 0.01% 1079
2021
Q3 		– Sell
-1,215
Closed -$188K – 1734
2021
Q2 		$188K Sell
1,215
-1,922
-61% -$279K 0.02% 1021
2021
Q1 		$495K Sell
3,137
-202
-6% -$42.6K 0.04% 524
2020
Q4 		$775K Buy
+3,339
New +$774K 0.08% 298
2019
Q4 		– Sell
-684
Closed -$99K – 1660
2019
Q3 		$99K Buy
+684
New +$92.7K 0.01% 1088
2018
Q4 		– Sell
-764
Closed -$195K – 1791
2018
Q3 		$195K Buy
+764
New +$211K 0.01% 1085
2018
Q2 		– Sell
-1,647
Closed -$332K – 2266
2018
Q1 		$332K Buy
+1,647
New +$328K 0.02% 985
2017
Q4 		– Sell
-1,220
Closed -$201K – 2699
2017
Q3 		$201K Buy
+1,220
New +$175K 0.01% 1852

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's KPTI Position: Q1 2024 in Review

Virtu Financial sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 667 shares — an estimated $9K sold.

Virtu Financial first reported a position in KPTI in Q3 2017 and held it in 9 quarters. The position peaked at $775K in Q4 2020. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • Virtu Financial reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Virtu Financial sold 667 Karyopharm Therapeutics shares in Q1 2024, an estimated $9K.
  • Virtu Financial first reported a position in Karyopharm Therapeutics in Q3 2017 and held it in 9 quarters.
  • Virtu Financial's Karyopharm Therapeutics position peaked at $775K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Virtu Financial's 13F filing for Q1 2024, filed 20 May 2024.